We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.5B
AUM Growth
+$891M
Cap. Flow
-$92.8M
Cap. Flow %
-0.89%
Top 10 Hldgs %
36.27%
Holding
147
New
14
Increased
53
Reduced
21
Closed
16

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$98.5M
2
SIEN
Sientra, Inc.
SIEN
+$54.3M
3
GILD icon
Gilead Sciences
GILD
+$50.4M
4
MGLN
Magellan Health Services, Inc.
MGLN
+$47.6M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$42.9M

Top Sells

Rank Stock Value
1
CFN
CAREFUSION CORPORATION
CFN
+$215M
2
A icon
Agilent Technologies
A
+$79M
3
ARWR icon
Arrowhead Research
ARWR
+$76.5M
4
STJ
St Jude Medical
STJ
+$54.8M
5
QGENF
QIAGEN NV
QGENF
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 85.82%
2 Financials 0.08%
3 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
51
DELISTED
Exact Sciences
EXAS
$48.8M 0.47%
1,778,000
+55,000
+3% +$1.34M
XNPT
52
DELISTED
XENOPORT, INC.
XNPT
$48.6M 0.46%
5,546,100
– –
PBYI icon
53
Puma Biotechnology
PBYI
$405M
$47.5M 0.45%
250,900
+38,000
+18% +$8.43M
CERS icon
54
Cerus
CERS
$585M
$43.9M 0.42%
7,035,000
-150,000
-2% -$681K
SPY icon
55
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$779B
$41.1M 0.39%
200,000
-150,000
-43% -$30.2M
CLVS
56
DELISTED
Clovis Oncology, Inc.
CLVS
$40M 0.38%
+714,100
New +$37.5M
PRQR icon
57
ProQR Therapeutics
PRQR
$246M
$39.6M 0.38%
1,829,400
+879,400
+93% +$13.3M
ISEE
58
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$38.7M 0.37%
861,800
+523,000
+154% +$22M
CLDX icon
59
Celldex Therapeutics
CLDX
$2.82B
$37.6M 0.36%
137,480
-7,960
-5% -$1.98M
AFMD
60
DELISTED
Affimed
AFMD
$36.1M 0.34%
581,463
– –
MDT icon
61
Medtronic
MDT
$112B
$35.7M 0.34%
493,800
+70,500
+17% +$4.9M
ARRY
62
DELISTED
Array Biopharma Inc
ARRY
$34.3M 0.33%
7,247,700
+844,900
+13% +$3.34M
CAH icon
63
Cardinal Health
CAH
$54.4B
$26.2M 0.25%
325,000
+48,000
+17% +$3.79M
COV
64
CALL
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$25.6M 0.24%
250,000
– –
LOXO
65
DELISTED
Loxo Oncology, Inc
LOXO
$25.6M 0.24%
2,175,857
– –
KYTH
66
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$25.1M 0.24%
+722,900
New +$25.2M
PTLA
67
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$24.1M 0.23%
850,700
– –
UNH icon
68
UnitedHealth
UNH
$387B
$23.8M 0.23%
235,000
+35,000
+18% +$3.32M
BHC icon
69
Bausch Health
BHC
$1.68B
$23.2M 0.22%
162,000
+24,000
+17% +$3.23M
TEVA icon
70
Teva Pharmaceuticals
TEVA
$40.1B
$23M 0.22%
400,000
-262,000
-40% -$14.6M
MRTX
71
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$21.6M 0.21%
1,167,000
– –
COV
72
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$21.6M 0.21%
211,200
+30,600
+17% +$2.94M
OSUR icon
73
OraSure Technologies
OSUR
$276M
$20.1M 0.19%
1,978,500
-3,393,500
-63% -$30.4M
FWP
74
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$20M 0.19%
+137,229
New +$19.8M
AMAG
75
DELISTED
AMAG Pharmaceuticals
AMAG
$20M 0.19%
469,000
+311,000
+197% +$11.2M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2014 Portfolio in Review

As of Q4 2014, OrbiMed held 147 positions worth $10.5B, up 9.3% from $9.57B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed's Q4 2014 filing shows 14 new, 53 increased, 21 reduced and 16 closed positions. Its largest new stake was Sientra, Inc.: 318,531 shares worth $53.5M. The largest sale was CAREFUSION CORPORATION, an estimated $215M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q4 2014 buy was Sientra, Inc.: 318,531 shares worth $53.5M.
  • OrbiMed added most to Biogen in Q4 2014, an estimated $98.5M increase.
  • OrbiMed's biggest Q4 2014 reduction was Agilent Technologies, cutting an estimated $79M.
  • OrbiMed fully exited CAREFUSION CORPORATION in Q4 2014, selling an estimated $215M.
  • OrbiMed's ten largest holdings make up 36% of its $10.5B portfolio in Q4 2014.
  • OrbiMed opened 14 new positions and closed 16 in Q4 2014.
  • OrbiMed's portfolio value rose 9.3% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q4 2014, filed 13 Feb 2015.